Stocklytics Platform
Asset logo for symbol JANX
Janux Therapeutics
JANX61
$62.75arrow_drop_up0.62%$0.39
Asset logo for symbol JANX
JANX61

$62.75

arrow_drop_up0.62%

Performance History

Chart placeholder
Key Stats
Open$62.95
Prev. Close$62.36
EPS-1.17
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range62.75
62.99
52 Week Range5.65
72.47
Ratios
EPS-1.17

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Janux Therapeutics (JANX)

Janux Therapeutics, Inc. (JANX) is a biopharmaceutical company that is focused on developing and commercializing novel immunotherapies for the treatment of cancer. The company's mission is to harness the power of the immune system to target and destroy cancer cells, with the goal of improving outcomes for patients. Janux Therapeutics is at the forefront of the rapidly growing field of immuno-oncology, which has the potential to revolutionize cancer treatment.
One of the key factors driving investor interest in JANX stock is the company's strong track record in developing innovative therapies. Janux Therapeutics has a pipeline of multiple drug candidates that are designed to target specific types of cancer cells, including solid tumors and hematological malignancies. These therapies are based on the company's proprietary platform technology, which enables the engineering of T-cell receptors (TCRs) that can recognize and bind to cancer-specific antigens. This approach has the potential to overcome some of the limitations of existing immunotherapies, such as CAR-T cells.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. David Alan Campbell Ph.D.
Headquarters
La Jolla
Employees
67
Exchange
NASDAQ
add Janux Therapeutics to watchlist

Keep an eye on Janux Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Janux Therapeutics's (JANX) price per share?

The current price per share for Janux Therapeutics (JANX) is $62.75. The stock has seen a price change of $0.39 recently, indicating a 0.63% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Janux Therapeutics (JANX)?

For Janux Therapeutics (JANX), the 52-week high is $72.47, which is 15.49% from the current price. The 52-week low is $5.65, the current price is 1.01K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Janux Therapeutics (JANX) a growth stock?

Janux Therapeutics (JANX) has shown an average price growth of -2.59% over the past three years. It has received a score of 95 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Janux Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Janux Therapeutics (JANX) stock price performance year to date (YTD)?

As of the latest data, Janux Therapeutics (JANX) has a year-to-date price change of 469.42%. Over the past month, the stock has experienced a price change of 16.9%. Over the last three months, the change has been 49.94%. Over the past six months, the figure is 44.65%.
help

Is Janux Therapeutics (JANX) a profitable company?

Janux Therapeutics (JANX) has a net income of -$58.29M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 75.81% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -8.16K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $8.08M, although specific revenue growth data is currently not available. The gross profit is $6.13M. Operating income is noted at -$72.98M. Furthermore, the EBITDA is -$83.88M.
help

What is the market capitalization of Janux Therapeutics (JANX)?

Janux Therapeutics (JANX) has a market capitalization of $3.66B. The average daily trading volume is 62.88, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level